Ignite Creation Date:
2025-12-25 @ 4:19 AM
Ignite Modification Date:
2025-12-26 @ 3:20 AM
Study NCT ID:
NCT05283720
Status:
RECRUITING
Last Update Posted:
2025-12-18
First Post:
2022-03-09
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'removedCountries': ['Canada', 'China', 'United Kingdom']}, 'conditionBrowseModule': {'meshes': [{'id': 'D008228', 'term': 'Lymphoma, Non-Hodgkin'}, {'id': 'D007943', 'term': 'Leukemia, Hairy Cell'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D012008', 'term': 'Recurrence'}, {'id': 'D016403', 'term': 'Lymphoma, Large B-Cell, Diffuse'}], 'ancestors': [{'id': 'D008223', 'term': 'Lymphoma'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D008232', 'term': 'Lymphoproliferative Disorders'}, {'id': 'D008206', 'term': 'Lymphatic Diseases'}, {'id': 'D006425', 'term': 'Hemic and Lymphatic Diseases'}, {'id': 'D007160', 'term': 'Immunoproliferative Disorders'}, {'id': 'D007154', 'term': 'Immune System Diseases'}, {'id': 'D007938', 'term': 'Leukemia'}, {'id': 'D006402', 'term': 'Hematologic Diseases'}, {'id': 'D020969', 'term': 'Disease Attributes'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}, {'id': 'D016393', 'term': 'Lymphoma, B-Cell'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000077269', 'term': 'Lenalidomide'}, {'id': 'C551803', 'term': 'ibrutinib'}, {'id': 'D000069283', 'term': 'Rituximab'}, {'id': 'D003520', 'term': 'Cyclophosphamide'}, {'id': 'D004317', 'term': 'Doxorubicin'}, {'id': 'D011241', 'term': 'Prednisone'}, {'id': 'C000600736', 'term': 'polatuzumab vedotin'}], 'ancestors': [{'id': 'D010797', 'term': 'Phthalimides'}, {'id': 'D010795', 'term': 'Phthalic Acids'}, {'id': 'D000146', 'term': 'Acids, Carbocyclic'}, {'id': 'D002264', 'term': 'Carboxylic Acids'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D010881', 'term': 'Piperidones'}, {'id': 'D010880', 'term': 'Piperidines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D054833', 'term': 'Isoindoles'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D058846', 'term': 'Antibodies, Monoclonal, Murine-Derived'}, {'id': 'D000911', 'term': 'Antibodies, Monoclonal'}, {'id': 'D000906', 'term': 'Antibodies'}, {'id': 'D007136', 'term': 'Immunoglobulins'}, {'id': 'D007162', 'term': 'Immunoproteins'}, {'id': 'D001798', 'term': 'Blood Proteins'}, {'id': 'D011506', 'term': 'Proteins'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}, {'id': 'D012712', 'term': 'Serum Globulins'}, {'id': 'D005916', 'term': 'Globulins'}, {'id': 'D010752', 'term': 'Phosphoramide Mustards'}, {'id': 'D009588', 'term': 'Nitrogen Mustard Compounds'}, {'id': 'D009150', 'term': 'Mustard Compounds'}, {'id': 'D006846', 'term': 'Hydrocarbons, Halogenated'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D063088', 'term': 'Phosphoramides'}, {'id': 'D009943', 'term': 'Organophosphorus Compounds'}, {'id': 'D003630', 'term': 'Daunorubicin'}, {'id': 'D018943', 'term': 'Anthracyclines'}, {'id': 'D009279', 'term': 'Naphthacenes'}, {'id': 'D011084', 'term': 'Polycyclic Aromatic Hydrocarbons'}, {'id': 'D006841', 'term': 'Hydrocarbons, Aromatic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D011083', 'term': 'Polycyclic Compounds'}, {'id': 'D000617', 'term': 'Aminoglycosides'}, {'id': 'D006027', 'term': 'Glycosides'}, {'id': 'D002241', 'term': 'Carbohydrates'}, {'id': 'D011244', 'term': 'Pregnadienediols'}, {'id': 'D011245', 'term': 'Pregnadienes'}, {'id': 'D011278', 'term': 'Pregnanes'}, {'id': 'D013256', 'term': 'Steroids'}, {'id': 'D000072473', 'term': 'Fused-Ring Compounds'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SEQUENTIAL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 496}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2022-06-14', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-12', 'completionDateStruct': {'date': '2032-11', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-12-16', 'studyFirstSubmitDate': '2022-03-09', 'studyFirstSubmitQcDate': '2022-03-09', 'lastUpdatePostDateStruct': {'date': '2025-12-18', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2022-03-17', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2032-11', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of Participants with Dose-Limiting Toxicities (DLT)', 'timeFrame': 'Up to Approximately 5 Years', 'description': 'DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications.'}], 'secondaryOutcomes': [{'measure': 'Best Overall Response (BOR) per Investigator', 'timeFrame': 'Up to Approximately 5 Years', 'description': 'BOR is defined as the percentage of participants who achieved best overall response of CR or PR by Lugano 2014 criteria as assessed by the investigator.'}, {'measure': 'Duration of response (DOR) per Investigator', 'timeFrame': 'Up to Approximately 5 Years', 'description': "DOR is defined for participants who achieved best overall response of CR or PR ('responders'), as the time in months from initial CR/PR to the earliest occurrence of radiographic progression determined by Lugano 2014 criteria as assessed by the investigator, or death from any cause."}, {'measure': 'Number of Participants with Progression-free survival (PFS)', 'timeFrame': 'Up to Approximately 5 Years', 'description': 'PFS is defined as the time in months from the first dose of study drug to the earliest occurrence of disease progression determined by Lugano 2014 criteria as assessed by investigator, or death from any cause.'}, {'measure': 'Percentage of Participants with Complete Response (CR)', 'timeFrame': 'Up to Approximately 5 Years', 'description': 'CR is defined as the percentage of participantswho achieved best overall response of CR determined by Lugano 2014 criteria as assessed by investigator.'}, {'measure': 'Time-to-response (TTR)', 'timeFrame': 'Up to Approximately 5 Years', 'description': "TTR is defined as the number of months from the date of first dose to the date of best overall response of CR or PR ('responders') determined by Lugano 2014 criteria as assessed by investigator."}, {'measure': 'Time to Next Antilymphoma Therapy (TTNT)', 'timeFrame': 'Up to Approximately 5 Years', 'description': 'Time to next antilymphoma therapy.'}, {'measure': 'Rate of Minimal Residual Disease (MRD) Negativity', 'timeFrame': 'Up to Approximately 5 Years', 'description': 'MRD is defined as the percentage of participants with assessment of the minimal residual disease.'}, {'measure': 'Overall Survival (OS)', 'timeFrame': 'Up to Approximately 5 Years', 'description': '(OS) is defined as the time in months from first dose of epcoritamab to death from any cause.'}]}, 'oversightModule': {'isUsExport': True, 'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Non-Hodgkin Lymphoma', 'Epcoritamab', 'Lenalidomide', 'Ibrutinib', 'Polatuzumab Vedotin', 'Rituximab', 'Cyclophosphamide', 'Doxorubicin Hydrochloride (HCl]', 'Prednisone (pola-R-CHP)', 'ABBV-GMAB-3013', 'Cancer', 'Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL), Venetoclax,', 'Venclexta', 'ABT-199', 'GDC-0199', 'CC-99282', 'EPCORE', 'Pirtobrutinib', 'Mantle Cell Lymhoma'], 'conditions': ['Non-Hodgkin Lymphoma']}, 'referencesModule': {'seeAlsoLinks': [{'url': 'https://www.abbvieclinicaltrials.com/study/?id=M22-132', 'label': 'Related Info'}]}, 'descriptionModule': {'briefSummary': 'B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purpose of this study is to assess the safety and tolerability of epcoritamab in combination with anti-neoplastic agents in adult participants with Non-Hodgkin lymphoma (NHL). Adverse events and change in disease activity will be assessed.\n\nEpcoritamab is an investigational drug being developed for the treatment of NHL. Study doctors put the participants in groups called treatment arms. The combination of epcoritamab with anti-neoplastic agents will be explored. Each treatment arm receives a different treatment combination depending on eligibility. Approximately 496 adult participants with NHL will be enrolled in 100 sites globally.\n\nIn both the dose escalation and dose expansion arms participants will receive subcutaneous (SC) epcoritamab in 28 day, 21 day, or 56 day cycles dependent on the arm in combination with the anti-neoplastic agents described below:\n\n1: Oral lenalidomide in participants (PPTS) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL); 2: Oral ibrutinib and oral lenalidomide in PPTS with R/R DLBCL; 3: Intravenous (IV) polatuzumab vedotin, IV rituximab, IV cyclophosphamide, IV doxorubicin hydrochloride (HCl), and oral prednisone (pola-R-CHP) in PPTS with newly diagnosed treatment-naïve DLBCL, or completion of treatment in 3B; 4: Oral CC-99282 in PPTS with R/R DLBCL; 5: Oral CC-99282 in PPTS with R/R follicular lymphoma (FL); 6A: Oral ibrutinib in PPTS with R/R mantle cell lymphoma (MCL).\n\nThere may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Diagnosis of:\n\n \\-- Diffuse large B-cell lymphoma (DLBCL) (de novo or histologically transformed from follicular lymphoma (FL) or nodal marginal zone lymphoma) with histologically confirmed CD20+ disease, inclusive of the following according to World Health Organization (WHO) 2016 classification and documented in pathology report:\n * DLBCL, not otherwise specified (NOS).\n * High-grade B cell lymphoma with MYC and BCL-2 and/or BCL-6 translocations per WHO 2016 ("double-hit" or "triple-hit") Note: High-grade B-cell lymphomas NOS or other double- /triple-hit lymphomas (with histologies not consistent with DLBCL) are not eligible.\n * Follicular lymphoma (FL) Grade 3B. OR\n* FL with histologically confirmed CD20+ Grade 1 to 3a and no evidence of histologic transformation to an aggressive lymphoma at most recent representative tumor biopsy, according to WHO 2016 classification. OR\n* Mantle cell lymphoma (MCL) with histologically confirmed CD20+ disease at most recent representative tumor biopsy according to the WHO 2016 classification with evidence of overexpression of cyclin D1 in association with relevant markers or evidence of t(11;14) assessed by flow cytometry, fluorescence in situ hybridization (FISH), or polymerase chain reaction (PCR).\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2, except for Arm 6A where ECOG performance status must be 0-1.\n* Must have 1 or more measurable disease sites:\n\n * A positron emission tomography (PET) /computed tomography (CT) scan demonstrating PET-positive lesion(s) AND\n * At least 1 measurable nodal lesion (long axis \\> 1.5 cm) or \\>= 1 measurable extra-nodal lesion (long axis \\> 1.0 cm) on CT scan or magnetic resonance imaging (MRI).\n\nExclusion Criteria:\n\n* Prior treatment with epcoritamab or any other bispecific antibody targeting CD3 and CD20.\n* Toxicities from prior anticancer therapy that have not resolved to Common Terminology Criteria for Adverse Events (CTCAE, v 5.0), Grade 2 or below, with the exception of alopecia. Other eligibility criteria (e.g., laboratory, cardiac criteria) must also be met.'}, 'identificationModule': {'nctId': 'NCT05283720', 'briefTitle': 'A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma', 'organization': {'class': 'INDUSTRY', 'fullName': 'Genmab'}, 'officialTitle': 'Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination With Anti-Neoplastic Agents in Subjects With Non-Hodgkin Lymphoma', 'orgStudyIdInfo': {'id': 'M22-132'}, 'secondaryIdInfos': [{'id': '2023-505347-38', 'type': 'OTHER', 'domain': 'EU CT'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Arm 1: Dose Escalation', 'description': 'Participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) will receive escalating doses of epcoritamab in combination with lenalidomide in 28 day cycles.', 'interventionNames': ['Drug: Epcoritamab', 'Drug: Lenalidomide']}, {'type': 'EXPERIMENTAL', 'label': 'Arm 2: Dose Escalation', 'description': 'Participants with R/R DLBCL will receive escalating doses of epcoritamab in combination with ibrutinib and lenalidomide in 28 day cycles.', 'interventionNames': ['Drug: Epcoritamab', 'Drug: Lenalidomide', 'Drug: Ibrutinib']}, {'type': 'EXPERIMENTAL', 'label': 'Arm 3: Dose Escalation', 'description': 'Participants with newly diagnosed treatment-naïve DLBCL will receive escalating doses of epcoritamab in combination with polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin hydrochloride (HCl), and prednisone (pola-R-CHP) in 21 day cycles.', 'interventionNames': ['Drug: Epcoritamab', 'Drug: Rituximab', 'Drug: Cyclophosphamide', 'Drug: Doxorubicin Hydrochloride [HCl]', 'Drug: Prednisone', 'Drug: Polatuzumab Vedotin']}, {'type': 'EXPERIMENTAL', 'label': 'Arm 4: Dose Escalation', 'description': 'Participants with R/R DLBCL will receive escalating doses of epcoritamab in combination with CC-99282 in 28 day cycles.', 'interventionNames': ['Drug: Epcoritamab', 'Drug: CC-99282']}, {'type': 'EXPERIMENTAL', 'label': 'Arm 5: Dose Escalation', 'description': 'Participants with R/R follicular lymphoma (FL) will receive escalating doses of epcoritamab in combination with CC-99282 in 28 day cycles.', 'interventionNames': ['Drug: Epcoritamab', 'Drug: CC-99282']}, {'type': 'EXPERIMENTAL', 'label': 'Arm 6A: Dose Escalation', 'description': 'Participants with R/R mantle cell lymphoma (MCL) will receive escalating doses of epcoritamab in combination with ibrutinib in 28 day cycles.', 'interventionNames': ['Drug: Epcoritamab', 'Drug: Ibrutinib']}, {'type': 'EXPERIMENTAL', 'label': 'Arm 1: Dose Expansion', 'description': 'Participants with R/R DLBCL will receive the recommended dose of epcoritamab in combination with lenalidomide in 28 day cycles.', 'interventionNames': ['Drug: Epcoritamab', 'Drug: Lenalidomide']}, {'type': 'EXPERIMENTAL', 'label': 'Arm 2: Dose Expansion', 'description': 'Participants with R/R DLBCL will receive the recommended dose of epcoritamab in combination with oral ibrutinib and oral lenalidomide in 28 day cycles.', 'interventionNames': ['Drug: Epcoritamab', 'Drug: Lenalidomide', 'Drug: Ibrutinib']}, {'type': 'EXPERIMENTAL', 'label': 'Arm 3: Dose Expansion', 'description': 'Participants newly diagnosed treatment-naïve DLBCL will receive the recommended dose of epcoritamab in combination with polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin hydrochloride (HCl), and prednisone (pola-R-CHP) in 21 day cycles.', 'interventionNames': ['Drug: Epcoritamab', 'Drug: Rituximab', 'Drug: Cyclophosphamide', 'Drug: Doxorubicin Hydrochloride [HCl]', 'Drug: Prednisone', 'Drug: Polatuzumab Vedotin']}, {'type': 'EXPERIMENTAL', 'label': 'Arm 3B: Dose Expansion', 'description': 'Participants newly diagnosed treatment-naïve DLBCL will receive the recommended dose of epcoritamab in combination with polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin hydrochloride (HCl), and prednisone (pola-R-CHP), in 21 day cycles,until unacceptable toxicity, withdrawal of consent, or completion of treatment.', 'interventionNames': ['Drug: Epcoritamab', 'Drug: Rituximab', 'Drug: Cyclophosphamide', 'Drug: Doxorubicin Hydrochloride [HCl]', 'Drug: Prednisone', 'Drug: Polatuzumab Vedotin']}, {'type': 'EXPERIMENTAL', 'label': 'Arm 4: Dose Expansion', 'description': 'Participants with R/R DLBCL will receive the recommended dose of epcoritamab in combination with CC-99282 in 28 day cycles.', 'interventionNames': ['Drug: Epcoritamab', 'Drug: CC-99282']}, {'type': 'EXPERIMENTAL', 'label': 'Arm 5: Dose Expansion', 'description': 'Participants with R/R FL will receive the recommended dose of epcoritamab in combination with CC-99282 in 28 day cycles.', 'interventionNames': ['Drug: Epcoritamab', 'Drug: CC-99282']}, {'type': 'EXPERIMENTAL', 'label': 'Arm 6: Dose Expansion', 'description': 'Participants with R/R MCL will receive the recommended dose of epcoritamab in combination with ibrutinib in 28 day cycles.', 'interventionNames': ['Drug: Epcoritamab', 'Drug: Ibrutinib']}], 'interventions': [{'name': 'Epcoritamab', 'type': 'DRUG', 'otherNames': ['ABBV-GMAB-3013;'], 'description': 'Subcutaneous Injection (SC)', 'armGroupLabels': ['Arm 1: Dose Escalation', 'Arm 1: Dose Expansion', 'Arm 2: Dose Escalation', 'Arm 2: Dose Expansion', 'Arm 3: Dose Escalation', 'Arm 3: Dose Expansion', 'Arm 3B: Dose Expansion', 'Arm 4: Dose Escalation', 'Arm 4: Dose Expansion', 'Arm 5: Dose Escalation', 'Arm 5: Dose Expansion', 'Arm 6: Dose Expansion', 'Arm 6A: Dose Escalation']}, {'name': 'Lenalidomide', 'type': 'DRUG', 'description': 'Oral; Capsule', 'armGroupLabels': ['Arm 1: Dose Escalation', 'Arm 1: Dose Expansion', 'Arm 2: Dose Escalation', 'Arm 2: Dose Expansion']}, {'name': 'Ibrutinib', 'type': 'DRUG', 'otherNames': ['Imbruvica'], 'description': 'Oral; Capsule', 'armGroupLabels': ['Arm 2: Dose Escalation', 'Arm 2: Dose Expansion', 'Arm 6: Dose Expansion', 'Arm 6A: Dose Escalation']}, {'name': 'Rituximab', 'type': 'DRUG', 'description': 'Intravenous (IV); Injection', 'armGroupLabels': ['Arm 3: Dose Escalation', 'Arm 3: Dose Expansion', 'Arm 3B: Dose Expansion']}, {'name': 'Cyclophosphamide', 'type': 'DRUG', 'description': 'IV; Injection', 'armGroupLabels': ['Arm 3: Dose Escalation', 'Arm 3: Dose Expansion', 'Arm 3B: Dose Expansion']}, {'name': 'Doxorubicin Hydrochloride [HCl]', 'type': 'DRUG', 'description': 'IV; Injection', 'armGroupLabels': ['Arm 3: Dose Escalation', 'Arm 3: Dose Expansion', 'Arm 3B: Dose Expansion']}, {'name': 'Prednisone', 'type': 'DRUG', 'description': 'Oral; Tablet', 'armGroupLabels': ['Arm 3: Dose Escalation', 'Arm 3: Dose Expansion', 'Arm 3B: Dose Expansion']}, {'name': 'Polatuzumab Vedotin', 'type': 'DRUG', 'description': 'IV; Injection', 'armGroupLabels': ['Arm 3: Dose Escalation', 'Arm 3: Dose Expansion', 'Arm 3B: Dose Expansion']}, {'name': 'CC-99282', 'type': 'DRUG', 'description': 'Oral; Capsule', 'armGroupLabels': ['Arm 4: Dose Escalation', 'Arm 4: Dose Expansion', 'Arm 5: Dose Escalation', 'Arm 5: Dose Expansion']}]}, 'contactsLocationsModule': {'locations': [{'zip': '85719', 'city': 'Tucson', 'state': 'Arizona', 'status': 'COMPLETED', 'country': 'United States', 'facility': 'The University of Arizona Cancer Center - North Campus /ID# 242219', 'geoPoint': {'lat': 32.22174, 'lon': -110.92648}}, {'zip': '06510', 'city': 'New Haven', 'state': 'Connecticut', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Yale University School of Medicine /ID# 242089', 'geoPoint': {'lat': 41.30815, 'lon': -72.92816}}, {'zip': '19713', 'city': 'Newark', 'state': 'Delaware', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Christiana Care Health Service /ID# 242301', 'geoPoint': {'lat': 39.68372, 'lon': -75.74966}}, {'zip': '33606', 'city': 'Tampa', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Tampa General Hospital /ID# 246748', 'geoPoint': {'lat': 27.94752, 'lon': -82.45843}}, {'zip': '30322', 'city': 'Atlanta', 'state': 'Georgia', 'status': 'COMPLETED', 'country': 'United States', 'facility': 'Winship Cancer Institute of Emory University /ID# 242153', 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'zip': '21201', 'city': 'Baltimore', 'state': 'Maryland', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'University of Maryland, Baltimore /ID# 242218', 'geoPoint': {'lat': 39.29038, 'lon': -76.61219}}, {'zip': '64114-4859', 'city': 'Kansas City', 'state': 'Missouri', 'status': 'COMPLETED', 'country': 'United States', 'facility': 'Alliance for Multispecialty Research (AMR) - Kansas City /ID# 242144', 'geoPoint': {'lat': 39.09973, 'lon': -94.57857}}, {'zip': '11042', 'city': 'Lake Success', 'state': 'New York', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Northwell Health - Monter Cancer Center /ID# 245435', 'geoPoint': {'lat': 40.77066, 'lon': -73.71763}}, {'zip': '10029', 'city': 'New York', 'state': 'New York', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Icahn School of Medicine at Mount Sinai /ID# 242123', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '28204', 'city': 'Charlotte', 'state': 'North Carolina', 'status': 'COMPLETED', 'country': 'United States', 'facility': 'Novant Health Presbyterian Medical Center /ID# 242148', 'geoPoint': {'lat': 35.22709, 'lon': -80.84313}}, {'zip': '27834', 'city': 'Greenville', 'state': 'North Carolina', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'East Carolina University - Brody School of Medicine /ID# 242506', 'geoPoint': {'lat': 35.61266, 'lon': -77.36635}}, {'zip': '27103', 'city': 'Winston-Salem', 'state': 'North Carolina', 'status': 'COMPLETED', 'country': 'United States', 'facility': 'Novant Health Forsyth Medical Center /ID# 242198', 'geoPoint': {'lat': 36.09986, 'lon': -80.24422}}, {'zip': '19107', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'status': 'COMPLETED', 'country': 'United States', 'facility': 'Thomas Jefferson University Hospital /ID# 242077', 'geoPoint': {'lat': 39.95238, 'lon': -75.16362}}, {'zip': '19111', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'status': 'COMPLETED', 'country': 'United States', 'facility': 'Fox Chase Cancer Center /ID# 242106', 'geoPoint': {'lat': 39.95238, 'lon': -75.16362}}, {'zip': '37916', 'city': 'Knoxville', 'state': 'Tennessee', 'status': 'COMPLETED', 'country': 'United States', 'facility': 'Thompson Cancer Survival Ctr /ID# 242150', 'geoPoint': {'lat': 35.96064, 'lon': -83.92074}}, {'zip': '79410', 'city': 'Lubbock', 'state': 'Texas', 'status': 'COMPLETED', 'country': 'United States', 'facility': 'Joe Arrington Cancer Research /ID# 242226', 'geoPoint': {'lat': 33.57786, 'lon': -101.85517}}, {'zip': '98104-3588', 'city': 'Seattle', 'state': 'Washington', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Swedish Cancer Institute /ID# 242269', 'geoPoint': {'lat': 47.60621, 'lon': -122.33207}}, {'zip': '98405', 'city': 'Tacoma', 'state': 'Washington', 'status': 'COMPLETED', 'country': 'United States', 'facility': 'MultiCare Institute for Research & Innovation /ID# 242127', 'geoPoint': {'lat': 47.25288, 'lon': -122.44429}}, {'zip': '625 00', 'city': 'Brno', 'state': 'Brno-mesto', 'status': 'RECRUITING', 'country': 'Czechia', 'facility': 'Fakultní Nemocnice Brno - Jihlavská /ID# 242683', 'geoPoint': {'lat': 49.19522, 'lon': 16.60796}}, {'zip': '500 05', 'city': 'Hradec Králové', 'state': 'Hradec Kralove', 'status': 'RECRUITING', 'country': 'Czechia', 'facility': 'Fakultní nemocnice Hradec Králové - Sokolská /ID# 241722', 'geoPoint': {'lat': 50.20923, 'lon': 15.83277}}, {'zip': '708 52', 'city': 'Ostrava', 'state': 'Ostrava-mesto', 'status': 'RECRUITING', 'country': 'Czechia', 'facility': 'Fakultni Nemocnice Ostrava /ID# 242684', 'geoPoint': {'lat': 49.83465, 'lon': 18.28204}}, {'zip': '128 00', 'city': 'Prague', 'state': 'Praha 17', 'status': 'RECRUITING', 'country': 'Czechia', 'facility': 'Vseobecna Fakultni Nemocnice v Praze /ID# 242685', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '8200', 'city': 'Aarhus', 'state': 'Central Jutland', 'status': 'RECRUITING', 'country': 'Denmark', 'facility': 'Aarhus Universitetshospital - Skejby /ID# 242670', 'geoPoint': {'lat': 56.15674, 'lon': 10.21076}}, {'zip': '9000', 'city': 'Aalborg', 'state': 'North Denmark', 'status': 'COMPLETED', 'country': 'Denmark', 'facility': 'Aalborg University Hospital /ID# 242734', 'geoPoint': {'lat': 57.048, 'lon': 9.9187}}, {'zip': '63100', 'city': 'Clermont', 'state': 'Auvergne-Rhône-Alpes', 'status': 'RECRUITING', 'country': 'France', 'facility': 'CHU Clermont-Ferrand /ID# 242344', 'geoPoint': {'lat': 45.97057, 'lon': 5.90702}}, {'zip': '35000', 'city': 'Rennes', 'state': 'Brittany Region', 'status': 'RECRUITING', 'country': 'France', 'facility': 'CHU de Rennes - PONTCHAILLOU /ID# 242339', 'geoPoint': {'lat': 48.11109, 'lon': -1.67431}}, {'zip': '54511', 'city': 'Vandœuvre-lès-Nancy', 'state': 'Meurthe-et-Moselle', 'status': 'RECRUITING', 'country': 'France', 'facility': 'Centre Hospitalier Régional Universitaire de Nancy - Hôpitaux de Brabois /ID# 242342', 'geoPoint': {'lat': 48.66115, 'lon': 6.17114}}, {'zip': '59037', 'city': 'Lille', 'state': 'Nord', 'status': 'RECRUITING', 'country': 'France', 'facility': 'CHRU Lille - Hopital Claude Huriez /ID# 242335', 'geoPoint': {'lat': 50.63391, 'lon': 3.05512}}, {'zip': '31059', 'city': 'Toulouse', 'state': 'Occitanie', 'status': 'RECRUITING', 'country': 'France', 'facility': 'IUCT Oncopole /ID# 242340', 'geoPoint': {'lat': 43.60426, 'lon': 1.44367}}, {'zip': '94010', 'city': 'Créteil', 'state': 'Paris', 'status': 'RECRUITING', 'country': 'France', 'facility': 'Hopitaux Universitaires Henri Mondor - Hopital Henri Mondor /ID# 242337', 'geoPoint': {'lat': 48.79266, 'lon': 2.46569}}, {'zip': '75010', 'city': 'Paris', 'state': 'Paris', 'status': 'RECRUITING', 'country': 'France', 'facility': 'Hôpital Saint-Louis /ID# 242336', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '44000', 'city': 'Nantes', 'state': 'Pays de la Loire Region', 'status': 'RECRUITING', 'country': 'France', 'facility': 'Centre Hospitalier Universitaire de Nantes, Hotel Dieu -HME /ID# 242345', 'geoPoint': {'lat': 47.21725, 'lon': -1.55336}}, {'zip': '69495', 'city': 'Pierre-Bénite', 'state': 'Rhone', 'status': 'RECRUITING', 'country': 'France', 'facility': 'HCL - Hopital Lyon Sud /ID# 242349', 'geoPoint': {'lat': 45.70359, 'lon': 4.82424}}, {'zip': '75013', 'city': 'Paris', 'state': 'Île-de-France Region', 'status': 'RECRUITING', 'country': 'France', 'facility': 'Hopital Pitie Salpetriere /ID# 242343', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '89081', 'city': 'Ulm', 'state': 'Baden-Wurttemberg', 'status': 'RECRUITING', 'country': 'Germany', 'facility': 'Universitaetsklinikum Ulm /ID# 244265', 'geoPoint': {'lat': 48.39841, 'lon': 9.99155}}, {'zip': '86156', 'city': 'Augsburg', 'state': 'Bavaria', 'status': 'RECRUITING', 'country': 'Germany', 'facility': 'Klinikum Augsburg /ID# 244523', 'geoPoint': {'lat': 48.37154, 'lon': 10.89851}}, {'zip': '97080', 'city': 'Würzburg', 'state': 'Bavaria', 'status': 'RECRUITING', 'country': 'Germany', 'facility': 'Universitaetsklinikum Wuerzburg /ID# 245453', 'geoPoint': {'lat': 49.79391, 'lon': 9.95121}}, {'zip': '35043', 'city': 'Marburg', 'state': 'Hesse', 'status': 'RECRUITING', 'country': 'Germany', 'facility': 'Universitaetsklinikum Giessen und Marburg /ID# 245308', 'geoPoint': {'lat': 50.80904, 'lon': 8.77069}}, {'zip': '04103', 'city': 'Leipzig', 'state': 'Saxony', 'status': 'RECRUITING', 'country': 'Germany', 'facility': 'Universitaetsklinikum Leipzig /ID# 245513', 'geoPoint': {'lat': 51.33962, 'lon': 12.37129}}, {'zip': '93042', 'city': 'Regensburg', 'status': 'RECRUITING', 'country': 'Germany', 'facility': 'Universitaetsklinikum Regensburg /ID# 244517', 'geoPoint': {'lat': 49.01513, 'lon': 12.10161}}, {'zip': '1085', 'city': 'Budapest', 'state': 'Budapest', 'status': 'RECRUITING', 'country': 'Hungary', 'facility': 'Semmelweis Egyetem /ID# 242454', 'geoPoint': {'lat': 47.49835, 'lon': 19.04045}}, {'zip': '4032', 'city': 'Debrecen', 'state': 'Hajdú-Bihar', 'status': 'RECRUITING', 'country': 'Hungary', 'facility': 'Debreceni Egyetem-Klinikai Kozpont /ID# 242450', 'geoPoint': {'lat': 47.53167, 'lon': 21.62444}}, {'zip': '7400', 'city': 'Kaposvár', 'state': 'Somogy County', 'status': 'RECRUITING', 'country': 'Hungary', 'facility': 'Somogy Varmegyei Kaposi Mor Oktato Korhaz /ID# 245935', 'geoPoint': {'lat': 46.36667, 'lon': 17.8}}, {'zip': '1122', 'city': 'Budapest', 'status': 'RECRUITING', 'country': 'Hungary', 'facility': 'Orszagos Onkologiai Intezet /ID# 242458', 'geoPoint': {'lat': 47.49835, 'lon': 19.04045}}, {'zip': '91120', 'city': 'Jerusalem', 'state': 'Jerusalem', 'status': 'RECRUITING', 'country': 'Israel', 'facility': 'Hadassah Medical Center-Hebrew University /ID# 243013', 'geoPoint': {'lat': 31.76904, 'lon': 35.21633}}, {'zip': '5265601', 'city': 'Ramat Gan', 'state': 'Tel Aviv', 'status': 'RECRUITING', 'country': 'Israel', 'facility': 'The Chaim Sheba Medical Center /ID# 243010', 'geoPoint': {'lat': 32.08227, 'lon': 34.81065}}, {'zip': '6423906', 'city': 'Tel Aviv', 'state': 'Tel Aviv', 'status': 'RECRUITING', 'country': 'Israel', 'facility': 'Tel Aviv Sourasky Medical Center /ID# 243012', 'geoPoint': {'lat': 32.08088, 'lon': 34.78057}}, {'zip': '4941492', 'city': 'Petah Tikva', 'status': 'RECRUITING', 'country': 'Israel', 'facility': 'Rabin Medical Center /ID# 243014', 'geoPoint': {'lat': 32.08707, 'lon': 34.88747}}, {'zip': '060-8648', 'city': 'Sapporo', 'state': 'Hokkaido', 'status': 'RECRUITING', 'country': 'Japan', 'facility': 'Hokkaido University Hospital /ID# 248999', 'geoPoint': {'lat': 43.06667, 'lon': 141.35}}, {'zip': '606-8507', 'city': 'Kyoto', 'state': 'Kyoto', 'status': 'COMPLETED', 'country': 'Japan', 'facility': 'Kyoto University Hospital /ID# 248997', 'geoPoint': {'lat': 35.02107, 'lon': 135.75385}}, {'zip': '104-0045', 'city': 'Chuo-ku', 'state': 'Tokyo', 'status': 'RECRUITING', 'country': 'Japan', 'facility': 'National Cancer Center Hospital /ID# 248995'}, {'zip': '6229 HX', 'city': 'Maastricht', 'state': 'Limburg', 'status': 'COMPLETED', 'country': 'Netherlands', 'facility': 'Maastricht Universitair Medisch Centrum /ID# 243317', 'geoPoint': {'lat': 50.84833, 'lon': 5.68889}}, {'zip': '1081 HV', 'city': 'Amsterdam', 'state': 'North Holland', 'status': 'RECRUITING', 'country': 'Netherlands', 'facility': 'Vrije Universiteit Medisch Centrum /ID# 243319', 'geoPoint': {'lat': 52.37403, 'lon': 4.88969}}, {'zip': '9713 GZ', 'city': 'Groningen', 'state': 'Provincie Groningen', 'status': 'RECRUITING', 'country': 'Netherlands', 'facility': 'Universitair Medisch Centrum Groningen /ID# 243318', 'geoPoint': {'lat': 53.21917, 'lon': 6.56667}}, {'zip': '2333 ZA', 'city': 'Leiden', 'state': 'South Holland', 'status': 'COMPLETED', 'country': 'Netherlands', 'facility': 'Leids Universitair Medisch Centrum /ID# 243316', 'geoPoint': {'lat': 52.15833, 'lon': 4.49306}}, {'zip': '3015 GD', 'city': 'Rotterdam', 'state': 'South Holland', 'status': 'COMPLETED', 'country': 'Netherlands', 'facility': 'Duplicate_Erasmus Medisch Centrum /ID# 243315', 'geoPoint': {'lat': 51.9225, 'lon': 4.47917}}, {'zip': '13620', 'city': 'Seongnam-si', 'state': 'Gyeonggido', 'status': 'RECRUITING', 'country': 'South Korea', 'facility': 'Seoul National University Bundang Hospital /ID# 242404', 'geoPoint': {'lat': 37.43861, 'lon': 127.13778}}, {'zip': '03080', 'city': 'Seoul', 'state': 'Seoul Teugbyeolsi', 'status': 'RECRUITING', 'country': 'South Korea', 'facility': 'Seoul National University Hospital /ID# 242402', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '05505', 'city': 'Seoul', 'state': 'Seoul Teugbyeolsi', 'status': 'RECRUITING', 'country': 'South Korea', 'facility': 'Asan Medical Center /ID# 242400', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '06351', 'city': 'Seoul', 'state': 'Seoul Teugbyeolsi', 'status': 'RECRUITING', 'country': 'South Korea', 'facility': 'Samsung Medical Center /ID# 242401', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '06591', 'city': 'Seoul', 'state': 'Seoul Teugbyeolsi', 'status': 'RECRUITING', 'country': 'South Korea', 'facility': 'The Catholic University of Korea, Seoul St. Marys Hospital /ID# 242403', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '08916', 'city': 'Badalona', 'state': 'Barcelona', 'status': 'RECRUITING', 'country': 'Spain', 'facility': 'Instituto Catalan de Oncologia (ICO) Badalona /ID# 243265', 'geoPoint': {'lat': 41.45004, 'lon': 2.24741}}, {'zip': '08035', 'city': 'Barcelona', 'state': 'Barcelona', 'status': 'RECRUITING', 'country': 'Spain', 'facility': 'Hospital Universitario Vall de Hebron /ID# 243260', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '08907', 'city': "L'Hospitalet de Llobregat", 'state': 'Barcelona', 'status': 'RECRUITING', 'country': 'Spain', 'facility': "Institut Català d'Oncologia (ICO) - L'Hospitalet /ID# 243261", 'geoPoint': {'lat': 41.35967, 'lon': 2.10028}}, {'zip': '28027', 'city': 'Madrid', 'state': 'Madrid', 'status': 'RECRUITING', 'country': 'Spain', 'facility': 'CLINICA UNIVERSIDAD DE NAVARRA-Madrid /ID# 243268', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '28040', 'city': 'Madrid', 'state': 'Madrid', 'status': 'RECRUITING', 'country': 'Spain', 'facility': 'Hospital Universitario Fundacion Jimenez Diaz /ID# 243264', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '28041', 'city': 'Madrid', 'state': 'Madrid', 'status': 'RECRUITING', 'country': 'Spain', 'facility': 'Hospital Universitario 12 de Octubre /ID# 243262', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '31008', 'city': 'Pamplona', 'state': 'Navarre', 'status': 'RECRUITING', 'country': 'Spain', 'facility': 'Clinica Universidad de Navarra - Pamplona /ID# 245031', 'geoPoint': {'lat': 42.81687, 'lon': -1.64323}}, {'zip': '37711', 'city': 'Salamanca', 'state': 'Salamanca', 'status': 'RECRUITING', 'country': 'Spain', 'facility': 'Hospital Universitario de Salamanca /ID# 243368', 'geoPoint': {'lat': 40.42972, 'lon': -3.67975}}, {'zip': '41013', 'city': 'Seville', 'state': 'Sevilla', 'status': 'RECRUITING', 'country': 'Spain', 'facility': 'Hospital Universitario Virgen del Rocio /ID# 243267', 'geoPoint': {'lat': 37.38283, 'lon': -5.97317}}, {'zip': '46010', 'city': 'Valencia', 'state': 'Valencia', 'status': 'RECRUITING', 'country': 'Spain', 'facility': 'Hospital Clinico Universitario de Valencia /ID# 243269', 'geoPoint': {'lat': 39.47391, 'lon': -0.37966}}, {'zip': '40447', 'city': 'Taichung', 'state': 'Taichung', 'status': 'RECRUITING', 'country': 'Taiwan', 'facility': 'China Medical University Hospital /ID# 242893', 'geoPoint': {'lat': 24.1469, 'lon': 120.6839}}, {'zip': '704', 'city': 'Tainan', 'state': 'Tainan', 'status': 'RECRUITING', 'country': 'Taiwan', 'facility': 'National Cheng Kung University Hospital /ID# 242894', 'geoPoint': {'lat': 22.99083, 'lon': 120.21333}}, {'zip': '11217', 'city': 'Taipei', 'state': 'Taipei', 'status': 'RECRUITING', 'country': 'Taiwan', 'facility': 'Taipei Veterans General Hosp /ID# 242892'}], 'centralContacts': [{'name': 'ABBVIE CALL CENTER', 'role': 'CONTACT', 'email': 'abbvieclinicaltrials@abbvie.com', 'phone': '844-663-3742'}], 'overallOfficials': [{'name': 'ABBVIE INC.', 'role': 'STUDY_DIRECTOR', 'affiliation': 'AbbVie'}]}, 'ipdSharingStatementModule': {'url': 'https://vivli.org/ourmember/abbvie/', 'infoTypes': ['STUDY_PROTOCOL', 'SAP'], 'timeFrame': 'For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/', 'ipdSharing': 'YES', 'description': 'AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.', 'accessCriteria': 'To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Genmab', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'AbbVie', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'SPONSOR'}}}}